Kainova Therapeutics
PrivateLast Round
Series B
Feb 10, 2026
Total Funding Raised
$72.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kainova Therapeutics is a biopharmaceutical company that develops breakthrough therapies targeting G protein-coupled receptors (GPCRs) for the treatment of immuno-oncology and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kainova Therapeutics Comparables
Compare Kainova Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GPCR Therapeutics | 84% | |
| Confo Therapeutics | 84% | |
| Pathios Therapeutics | 82% |
Kainova Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| Grant | Jan 25, 2024 | ||||
| Series A | May 10, 2022 | ||||
| Grant | Jan 27, 2022 | ||||
| Debt | Jan 13, 2020 | ||||
VC Round | May 28, 2019 |
Key People
Founding team and executive leadership
Kainova Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Series B |
| Idinvest Partners | VC Round |
| CTI Life Sciences Fund | Series B, Series A |
| Alsace Inter Regio Fonds d’Investissement | VC Round |
| Andera Partners | VC Round |
| Agence Nationale de la Recherche | Grant |
| 3B FUTURE Health Fund | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 33% MoM, reaching 1.8K.
- May 17, 2026
Monthly visitors grew 38% MoM, reaching 1.2K.
Kainova Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Kainova Therapeutics's valuation, stock price, and market status.
Is Domain Therapeutics a public or private company?
Domain Therapeutics is a private company.
What is the current stock price of Domain Therapeutics?
Domain Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Domain Therapeutics worth (valuation)?
Valuation information for Domain Therapeutics is not publicly available.
Can I buy Domain Therapeutics stock?
Domain Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Domain Therapeutics's last funding round?
Domain Therapeutics's most recent funding round was Series A on May 10, 2022.
Who are the main investors in Domain Therapeutics?
Key investors in Domain Therapeutics include 3B FUTURE Health Fund, Seventure Partners.
Will Domain Therapeutics IPO soon?
No public IPO plans have been announced for Domain Therapeutics.
How can I track Domain Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Domain Therapeutics's secondary market activity and sign up for updates.